Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 66,373 shares, a decrease of 59.3% from the October 15th total of 162,935 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 90,729 shares, the short-interest ratio is presently 0.7 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Soligenix has a consensus rating of “Sell”.
Get Our Latest Research Report on SNGX
Soligenix Price Performance
Shares of SNGX stock traded down $0.03 during midday trading on Monday, hitting $0.29. The company had a trading volume of 224,987 shares, compared to its average volume of 2,290,071. The stock has a market cap of $6.71 million, a price-to-earnings ratio of -0.64 and a beta of 2.04. The company’s 50 day simple moving average is $0.36 and its 200 day simple moving average is $0.64. Soligenix has a 52-week low of $0.28 and a 52-week high of $1.70.
Soligenix (NASDAQ:SNGX – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. Analysts anticipate that Soligenix will post -0.55 EPS for the current year.
Soligenix Company Profile
Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.
See Also
- Five stocks we like better than Soligenix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
